Cyproheptadine Hydrochloride Tablet
NDC Package 42708-177-21

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Cyproheptadine Hydrochloride tablets is perennial and seasonal allergic rhinitisVasomotor rhinitisAllergic conjunctivitis due to inhalant allergens and foodsMild, uncomplicated allergic skin manifestations of urticaria and angioedema.Amelioration of allergic reactions to blood or plasmaCold urticariaDermatographismAs therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. This formulation utilizes a tablet delivery system. Marketed by Qpharma Inc, this product is identified by NDC 42708-177 and is authorized under FDA application ANDA206553.

Identification & Billing

NDC Package Code
42708-177-21
Package Description
21 TABLET in 1 BOTTLE, PLASTIC
Product Code
42708-177
11-Digit Billing Format
42708017721
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Cyproheptadine Hydrochloride
Non-Proprietary Name
Cyproheptadine Hydrochloride
Substance Name
Cyproheptadine Hydrochloride
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
CYPROHEPTADINE HYDROCHLORIDE 4 mg/1
Usage Information
Perennial and seasonal allergic rhinitisVasomotor rhinitisAllergic conjunctivitis due to inhalant allergens and foodsMild, uncomplicated allergic skin manifestations of urticaria and angioedema.Amelioration of allergic reactions to blood or plasmaCold urticariaDermatographismAs therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled.

Regulatory & Marketing

Labeler Name
Qpharma Inc
Product Type
Human Prescription Drug
FDA Application #
ANDA206553
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
01-17-2017
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
Yes

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 42708-177-21 identifies a specific commercial package of 21 tablet in 1 bottle, plastic of Cyproheptadine Hydrochloride, a human prescription drug labeled by Qpharma Inc. This tablet is formulated for oral use and contains cyproheptadine hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Qpharma Inc on January 17, 2017. The current certification is valid through December 31, 2026.

How is this Qpharma Inc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 42708017721. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
42708-177-21
11-Digit CMS (5-4-2)
42708-0177-21

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.